Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/148239

Título:	Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens
Autor/a:	Vidal Crespo, Anna; Matas Céspedes, Alba; Rodríguez, Vanina; Rossi, Cédric; Valero, Juan G.; Serrat, Neus; Sanjuan Pla, Alejandra; Menéndez Buján, Pablo; Roué, Gaël; López Guillermo, Armando; Giné Soca, Eva; Campo Güerri, Elias; Colomer Pujol, Dolors; Bezombes, Christine; Lammerts van Bueren, J.; Chiu, Christopher; Doshi, Parul; Pérez Galán, Patricia
Notas:	CD38 is expressed in several types of non-Hodgkin lymphoma and constitutes a promising target for antibody-based therapy. Daratumumab (Darzalex) is a first-in-class anti-CD38 antibody approved for the treatment of relapsed/refractory multiple myeloma. It has also demonstrated clinical activity in Waldenstrom macroglobulinaemia and amyloidosis. Here, we have evaluated the activity and mechanism of action of daratumumab in preclinical in vitro and in vivo models of mantle cell lymphoma, follicular lymphoma and diffuse large B cell lymphoma, as monotherapy or in combination with standard chemo-immunotherapy. In vitro, daratumumab engages Fc-mediated cytotoxicity by antibody-dependent cell cytotoxicity and antibody-dependent cell phagocytosis in all lymphoma subtypes. In the presence of human serum, complement-dependent cell cytotoxicity was marginally engaged. We demonstrated by Selective Plane Illumination Microscopy that daratumumab fully penetrated a 3D lymphoma organoid and decreased organoid volume. In vivo, daratumumab completely prevents tumor outgrowth in models of mantle cell and follicular lymphoma, and shows comparable activity to rituximab in a disseminated in vivo model of blastic mantle cell lymphoma. Moreover, daratumumab improves overall survival in a mouse model of transformed CD20dim follicular lymphoma, where rituximab showed limited activity. Daratumumab potentiates the antitumor activity of CHOP and R-CHOP in mantle cell and follicular lymphoma xenografts. Furthermore, in a patient-derived diffuse large B cell lymphoma xenograft model, daratumumab anti-tumor activity was comparable to R-CHOP and the addition of daratumumab to either CHOP or R-CHOP led to full tumor regression. In summary, daratumumab constitutes a novel therapeutic opportunity in certain scenarios and these results warrant further clinical development.
Materia(s):	-Malaltia de Hodgkin -Limfomes -Cèl·lules B -Hodgkin's disease -Lymphomas -B cells
Derechos:	(c) Ferrata Storti Foundation, 2019
Tipo de documento:	Artículo Artículo - Versión publicada
Editor:	Ferrata Storti Foundation
Compartir:

Mostrar el registro completo del ítem